About Us
About us
We are Valerio Therapeutics, a clinical-stage biotechnology company pioneering the development of DNA decoy therapies. Using our revolutionary platON™ DNA decoy platform, we are developing innovative treatments that target and disrupt intracellular processes in tumors and inflammatory diseases by acting as decoys to hijack pathways critical to maintaining pathology.
Our Team
Management
Board of Directors
Scientific Advisory Committee
Company Profile
Valerio Therapeutics is a clinical-stage biotechnology company designing and developing novel and first-in-class DNA-decoy therapies targeting proteins implicated in tumors and inflammatory disease processes.
Our therapeutic strategy focuses on fighting intracellular pathways dysregulations, in fields that pose greater therapeutic challenges. Our approach is based upon unique mechanisms of action on intracellular DNA-binding proteins. We focus on bringing first-in-class and disruptive compounds from preclinical research to proof-of-concept in human cancer and inflammatory indications with high unmet needs.
We seek to transform breakthrough scientific opportunities into treatments through translational and clinical expertise, developing products to the stage where they are compelling opportunities for partners. Therefore, we are focused on advancing products from the preclinical stage to optimal inflection points (usually phase 2 clinical proof-of-concept studies). Once proof of concept is established, we seek to monetize the assets through various types of deals, thereby generating revenue and value.
Our inherent value rests on the significant potential of our product pipeline and the expertise of our highly professional team.
Our People
We are a passionate team of scientists and business professionals, with robust in-house translational and clinical expertise to drive our programs to their maximum value-inflection points and generate value and growth through collaborations.
We are led by a senior management team with extensive life sciences industry experience in international venues and a proven track record in translational research, clinical development, regulatory affairs and business development.
Our Science
Our proprietary platform of decoy oligonucleotides, platON™, generates innovative compounds targeting intracellular DNA-binding proteins implicated in tumors and inflammatory disease processes through a decoy mechanism.
This mechanism of action is unlike any other investigated or available today in these fields and has the capacity to address new and multiple intracellular pathways.
